Abstract

The Japan Diabetes Complication and its Prevention prospective (JDCP) study is a large-scale observational study conducted to investigate the current status of the management of people with diabetes, and to clarify the risk factors for the onset and progression of diabetes complications. The study includes 6338 patients aged 40 to <75 years who had received regular outpatient treatment from 2007–2009 at medical facilities nationwide specializing in diabetes. The primary endpoints for the study include occurrence and/or progression of nephropathy, retinopathy, neuropathy, macroangiopathy, and periodontal disease; the secondary endpoints include occurrence of malignancy and mortality. This report gives an outline of the study and a summary of the baseline data for participating patients with type 2 diabetes (n = 5944). The baseline characteristics were: men, 60.1 %; mean age, 61.4 years; duration of diabetes, 10.8 years; family history of diabetes, 52.8 %; BMI, 24.5 kg/m2; HbA1c, 7.4 % (achievement of <7.0, 40.6 %); blood pressure, 129.8/74.8 mmHg; and non-HDL-C, 137.6 mg/dL. Treatments included: diet therapy alone, 10.4 %, oral hypoglycemic agents, 62.1 %; and insulin therapy, 27.5 %. The cohort is to be followed up for at least 5 years, with a high follow-up rate. The focus of the study is to develop a clinical registry that is reliable and versatile and to bring the research findings and insights to bear on the society’s Treatment Guide for Diabetes.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.